With part of his fortune made in the software business, Dietmar Hopp has taken a sizable interest in biotech. His investment group, dievini Hopp BioTech Holding, has committed $104 million to back Germany's CureVac as the biotech company readies for new trials of RNA vaccinations against prostate and non-small cell lung cancers. Hopp, the former CEO and chairman of SAP, might face a much longer product-development cycle in biotech than in the software game. CureVac, whose cancer vaccines are in mid-stage development, doesn't expect Phase III studies of its prostate cancer vaccine to wrap up until 2020. In theory, if you started today, you could build the next Facebook and cash out as a billionaire before 2020. Indeed, biotech is a much different business that requires entrepreneurs to commit years of their lives before they even find out whether they have a product, depending on the outcomes of clinical trials. FierceBiotech article